New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk

July 2013

New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk.

This is a case of labeling catching up with the evidence.

Bisphosphonates persist in the bones for years, so 3 to 5 years of therapy is enough for many patients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote